Embecta Corp.

NASDAQ:EMBC

Drug Manufacturers - Specialty & Generic

Healthcare
$6.09 +0.65%

+$0.02 today

Market cap
$345.06M
Beta
0.81
P/E (TTM)
1.6
EPS (TTM)
$1.92
Dividend yield
14.79%
52W Low $2.77High $15.55

Volume 0.72M

Average 1.95M

EMBC Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Embecta Corp.NASDAQ: EMBC

Accounts Receivables · Q2 FY2026 · quarter ended Mar 2026

Accounts receivables turns positive

Q2 FY2026 accounts receivables was $11.3M, compared with -$2.1M a year earlier. Trailing-twelve-month accounts receivables was $39.8M. Over 3 fiscal years it compounded at -28.8% a year.

Context

  • Accounts receivables amounted to 4.1% of revenue in FY2025, down 11.5 pp from a year earlier.
  • Accounts receivables increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly accounts receivables holds near $11.3M or moves back toward the trailing-twelve-month quarterly average of $9.95M.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$11.3M+194.2% QoQ
Last fiscal yearSep 2025
$44.2M+125.3% YoY
LTMMar 2026
$39.8M+161.9% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+638.1%——
1 year+125.3%——
3-year CAGR-28.8%——
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
44.2M USD
Year-over-year change
+125.3%

Accounts Receivables vs competitors

How EMBC compares with its peers on the latest reported figures

  • EMBC's LTM Mar 2026 accounts receivables of $39.8M is the 3rd largest of the 11 companies compared; the peer median is $1.35M.
  • Its year-over-year change of +161.9% is the 6th highest of 11, against a peer median of +150.0%.
  • Accounts receivables amounts to 3.8% of revenue for EMBC, versus a peer median of 3.0%.
EMBC Competitors Peer median
Accounts Receivables for EMBC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
EVHEvolent Health, Inc.LTM Mar 2026$85.22M +3185.5%—4.5%
EBSEmergent BioSolutions Inc.LTM Mar 2026$59.9M +225.6%-40.0%8.9%
EMBCEmbecta Corp.LTM Mar 2026$39.8M +161.9%-28.8%3.8%
CDNACareDx, IncLTM Jun 2026$24.82M +2952.8%—5.4%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026$3.65M +482.9%—7.3%
MRVIMaravai LifeSciences Holdings, Inc.LTM Jun 2026$3.47M -166.1%—1.7%
MYGNMyriad Genetics, Inc.LTM Mar 2026$3.3M -17.5%-7.0%0.4%
SIGASIGA Technologies, Inc.LTM Mar 2026$2.68M -75.5%-22.4%2.9%
PSNLPersonalis, Inc.LTM Mar 2026$2.05M -650.8%—3.2%
PRMEPrime Medicine, Inc.LTM Mar 2026$17K +200.0%—0.4%
VIRVir Biotechnology, Inc.LTM Mar 2026$0 +100.0%—0.0%
Peer median (excluding EMBC) $1.35M+150.0%-22.4%3.0%

Competitors are the stored peer set for EMBC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Net Income415M223.6M70.4M78.3M95.4M
Depreciation & Amortization38M31.7M32.6M36.2M40.7M
Deferred Income Tax(2M)(26.5M)14.3M(70.6M)17.6M
Stock-Based Compensation12.8M18.7M21.5M26.3M31.6M
Change in Working Capital(32M)92.4M(80M)(47.7M)(23.7M)
Accounts Receivables(32M)122.7M7M(174.7M)44.2M
Inventory(18M)(23.4M)(28.8M)(16.5M)(6.1M)
Accounts Payables30M73.3M7.9M60M(68.9M)
Other Working Capital(12M)(80.2M)(66.1M)83.5M7.1M
Other Non-Cash Items24.2M72.3M8.9M13.2M30.1M
Operating Cash Flow456M412.2M67.7M35.7M191.7M
Capital Expenditures(39M)(24M)(26.5M)(15.8M)(9.3M)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(39M)(24M)(26.5M)(15.8M)(9.3M)
Debt Repayment01.44B(10.7M)(35.9M)(186M)
Common Stock Issued00000
Common Stock Repurchased00(3.6M)(3M)(5.7M)
Dividends Paid0(8.6M)(34.4M)(34.5M)(35M)
Other Financing Activities(417M)(1.48B)000
Financing Cash Flow(417M)(48M)(48.7M)(73.4M)(226.7M)
Effect of Forex Changes0(9.3M)3.1M1.2M(1.3M)
Net Change in Cash0330.9M(4.4M)(52.3M)(45.6M)
Free Cash Flow417M388.2M41.2M19.9M182.4M

Embecta Corp.

NASDAQ:EMBC

Intrinsic Alpha fair value

Locked

Current Price

$6.09

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.